Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno

Detalhes bibliográficos
Autor(a) principal: Lagares, Érika Barbosa
Data de Publicação: 2013
Outros Autores: Santos, Kelly de Freitas, Mendes, Raquel Cristina, Moreira, Fabiane Aparecida, Anastácio, Lucilene Rezende
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/525
Resumo: Introduction: Excessive weight gain is often reported in patients with breast cancer in hormoninotherapy with tamoxifen. Objectives: To describe the prevalence of overweight in women undergoing hormoninotherapy with tamoxifen and associated factors. Method: This was a descriptive and cross sectional study conducted in women diagnosed with breast cancer undergoing hormoninotherapy with tamoxifen. We collected information on nutritional status using anthropometric parameters such as body mass index (BMI), waist circumference and body fat percentage by bioelectrical impedance. Demographic, socioeconomic, lifestyle and clinical variables (weight, height, waist circumference, skin fold thickness and blood pressure) and dietary (24 hour recall) were collected. Results: We evaluated 24 patients aged 36-73 with a mean time of tamoxifen therapy of 16.6 months (range 4-60 months). Considering the classification of BMI, 52.4% (n=10) patients were diagnosed with overweight, 45.8% (n=11) with obesity and 1.8% (n=3) with normal weight. As for body fat percentage, two (8.3%) were overweight and 22 (91.7%) were obsese. Besides, 87.5% (n=21) were classified as having some degree of obesity. Conclusion: There was a prevalence of overweight and obesity in the evaluated women in hormoninotherapy with tamoxifen. Thus, patients, especially those who already had a history of overweight, should receive nutritional advice from the start of hormoninotherapy that promotes the maintenance of healthy weight, and should be encouraged to engage in programs of lifestyle changes.  
id INCA-1_f8d356a2cdf81a760117380e539cd27b
oai_identifier_str oai:rbc.inca.gov.br:article/525
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with TamoxifenoEl Sobrepeso en Mujeres Diagnosticadas con Cáncer de Mama en Hormonoterapia con TamoxifenoExcesso de Peso em Mulheres com Diagnóstico de Câncer de Mama em Hormonioterapia com TamoxifenoNeoplasias da MamaHormôniosTamoxifenoGanho de PesoAvaliação NutricionalBreast NeoplasmsHormonesTamoxifenWeight GainNutrition AssessmentNeoplasias de la MamaHormonasTamoxifenoAumento de PesoEvaluación NutricionalIntroduction: Excessive weight gain is often reported in patients with breast cancer in hormoninotherapy with tamoxifen. Objectives: To describe the prevalence of overweight in women undergoing hormoninotherapy with tamoxifen and associated factors. Method: This was a descriptive and cross sectional study conducted in women diagnosed with breast cancer undergoing hormoninotherapy with tamoxifen. We collected information on nutritional status using anthropometric parameters such as body mass index (BMI), waist circumference and body fat percentage by bioelectrical impedance. Demographic, socioeconomic, lifestyle and clinical variables (weight, height, waist circumference, skin fold thickness and blood pressure) and dietary (24 hour recall) were collected. Results: We evaluated 24 patients aged 36-73 with a mean time of tamoxifen therapy of 16.6 months (range 4-60 months). Considering the classification of BMI, 52.4% (n=10) patients were diagnosed with overweight, 45.8% (n=11) with obesity and 1.8% (n=3) with normal weight. As for body fat percentage, two (8.3%) were overweight and 22 (91.7%) were obsese. Besides, 87.5% (n=21) were classified as having some degree of obesity. Conclusion: There was a prevalence of overweight and obesity in the evaluated women in hormoninotherapy with tamoxifen. Thus, patients, especially those who already had a history of overweight, should receive nutritional advice from the start of hormoninotherapy that promotes the maintenance of healthy weight, and should be encouraged to engage in programs of lifestyle changes.  Introducción: El incremento de peso excesivo es a menudo relatado en pacientes con cáncer de mama en hormonoterapia con tamoxifeno. Objetivos: Describir la prevalencia de sobrepeso en mujeres sometidas a hormonoterapia com tamoxifeno y los factores asociados. Método: Tratase de un estudio descriptivo y transversal realizado en mujeres diagnosticadas con cáncer de mama sometidas a hormonoterapia con tamoxifeno. Han sido recolectadas informaciones referentes al estado nutricional mediante parámetros antropométricos como el Índice de Masa Corporal (IMC), la circunferencia de cintura y el porcentaje de grasa corporal por la bioimpedancia eléctrica. Características demográficas, socioeconómicas, estilo de vida y variables clínicas (peso, estatura, circunferencia de la cintura, pliegues cutáneos y tensión arterial) y la dieta (recordatorio 24 horas) han sido recolectadas. Resultados: Han sido evaluadas 24 pacientes en la franja de edad entre los 36 y los 73 años con un tiempo promedio de utilización del tamoxifeno de 16,6 meses (rango 4-60 meses). Teniendo en cuenta la clasificación del IMC, 52,4% (n=10) de las pacientes han sido diagnosticadas con sobrepeso, 45,8% (n=11) con obesidad y el 1,8% (n=3) con eutrofia. En cuanto al porcentaje de grasa corporal, de los (8,3%) tenían sobrepeso y 22 (91,7%), obesidad. Además, el 87,5% (n=21) han sido clasificadas con algún grado de obesidad abdominal. Conclusión: Hubo una prevalencia de sobrepeso y obesidad en las mujeres en hormonoterapia con tamoxifeno evaluadas. Así, las pacientes, especialmente aquellas que ya presentan un historial de sobrepeso, deben recibir asesoramiento nutricional desde el inicio de la hormonoterapia que promueve el mantenimiento del peso saludable, y deben ser animadas a participar en programas de cambios de estilo de vida.  Introdução: O ganho de peso excessivo é frequentemente relatado em pacientes com câncer de mama em hormonioterapia com tamoxifeno. Objetivos: Descrever a prevalência de excesso de peso em mulheres submetidas à hormonioterapia com tamoxifeno e fatores associados. Método: Trata-se de estudo descritivo e transversal realizado em mulheres com diagnóstico de câncer de mama submetidas à hormonioterapia com tamoxifeno. Foram coletadas informações referentes ao estado nutricional usando parâmetros antropométricos como Índice de Massa Corporal (IMC), circunferência da cintura e percentual de gordura corporal pela bioimpedanciometria. Características demográficas, socioeconômicas, estilo de vida e variáveis clínicas (peso, estatura, circunferência de cintura, dobras cutâneas e pressão arterial) e dietéticas (recordatório 24 horas) foram coletadas. Resultados: Foram avaliadas 24 pacientes na faixa etária de 36 a 73 anos, com tempo medio de uso do tamoxifeno de 16,6 meses (variando de 4 a 60 meses). Considerando-se a classificação de IMC, 52,4% (n=10) das pacientes foram diagnosticadas com sobrepeso, 45,8% (n=11) com obesidade e 1,8% (n=3) com eutrofia. Quanto ao percentual de gordura corporal, duas (8,3%) possuíam sobrepeso e 22 (91,7%), obesidade. Além disso, 87,5% (n=21) foram classificadas como tendo algum grau de obesidade abdominal. Conclusão: Houve predomínio de sobrepeso e obesidade nas mulheres em hormonioterapia com tamoxifeno avaliadas. Assim, as pacientes, principalmente aquelas que ja apresentam histórico de excesso de peso, devem receber orientações nutricionais, desde o início da hormonioterapia, que promovam a manutenção do peso saudável, e devem ser estimuladas a se engajar em programas de mudanças no estilo de vida.  INCA2013-06-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/52510.32635/2176-9745.RBC.2013v59n2.525Revista Brasileira de Cancerologia; Vol. 59 No. 2 (2013): Apr./May/June; 201-210Revista Brasileira de Cancerologia; Vol. 59 Núm. 2 (2013): abr./mayo/jun.; 201-210Revista Brasileira de Cancerologia; v. 59 n. 2 (2013): abr./maio/jun. ; 201-2102176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/525/320Lagares, Érika BarbosaSantos, Kelly de FreitasMendes, Raquel Cristina Moreira, Fabiane Aparecida Anastácio, Lucilene Rezende info:eu-repo/semantics/openAccess2021-11-29T20:11:55Zoai:rbc.inca.gov.br:article/525Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:11:55Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
El Sobrepeso en Mujeres Diagnosticadas con Cáncer de Mama en Hormonoterapia con Tamoxifeno
Excesso de Peso em Mulheres com Diagnóstico de Câncer de Mama em Hormonioterapia com Tamoxifeno
title Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
spellingShingle Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
Lagares, Érika Barbosa
Neoplasias da Mama
Hormônios
Tamoxifeno
Ganho de Peso
Avaliação Nutricional
Breast Neoplasms
Hormones
Tamoxifen
Weight Gain
Nutrition Assessment
Neoplasias de la Mama
Hormonas
Tamoxifeno
Aumento de Peso
Evaluación Nutricional
title_short Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
title_full Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
title_fullStr Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
title_full_unstemmed Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
title_sort Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
author Lagares, Érika Barbosa
author_facet Lagares, Érika Barbosa
Santos, Kelly de Freitas
Mendes, Raquel Cristina
Moreira, Fabiane Aparecida
Anastácio, Lucilene Rezende
author_role author
author2 Santos, Kelly de Freitas
Mendes, Raquel Cristina
Moreira, Fabiane Aparecida
Anastácio, Lucilene Rezende
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Lagares, Érika Barbosa
Santos, Kelly de Freitas
Mendes, Raquel Cristina
Moreira, Fabiane Aparecida
Anastácio, Lucilene Rezende
dc.subject.por.fl_str_mv Neoplasias da Mama
Hormônios
Tamoxifeno
Ganho de Peso
Avaliação Nutricional
Breast Neoplasms
Hormones
Tamoxifen
Weight Gain
Nutrition Assessment
Neoplasias de la Mama
Hormonas
Tamoxifeno
Aumento de Peso
Evaluación Nutricional
topic Neoplasias da Mama
Hormônios
Tamoxifeno
Ganho de Peso
Avaliação Nutricional
Breast Neoplasms
Hormones
Tamoxifen
Weight Gain
Nutrition Assessment
Neoplasias de la Mama
Hormonas
Tamoxifeno
Aumento de Peso
Evaluación Nutricional
description Introduction: Excessive weight gain is often reported in patients with breast cancer in hormoninotherapy with tamoxifen. Objectives: To describe the prevalence of overweight in women undergoing hormoninotherapy with tamoxifen and associated factors. Method: This was a descriptive and cross sectional study conducted in women diagnosed with breast cancer undergoing hormoninotherapy with tamoxifen. We collected information on nutritional status using anthropometric parameters such as body mass index (BMI), waist circumference and body fat percentage by bioelectrical impedance. Demographic, socioeconomic, lifestyle and clinical variables (weight, height, waist circumference, skin fold thickness and blood pressure) and dietary (24 hour recall) were collected. Results: We evaluated 24 patients aged 36-73 with a mean time of tamoxifen therapy of 16.6 months (range 4-60 months). Considering the classification of BMI, 52.4% (n=10) patients were diagnosed with overweight, 45.8% (n=11) with obesity and 1.8% (n=3) with normal weight. As for body fat percentage, two (8.3%) were overweight and 22 (91.7%) were obsese. Besides, 87.5% (n=21) were classified as having some degree of obesity. Conclusion: There was a prevalence of overweight and obesity in the evaluated women in hormoninotherapy with tamoxifen. Thus, patients, especially those who already had a history of overweight, should receive nutritional advice from the start of hormoninotherapy that promotes the maintenance of healthy weight, and should be encouraged to engage in programs of lifestyle changes.  
publishDate 2013
dc.date.none.fl_str_mv 2013-06-28
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/525
10.32635/2176-9745.RBC.2013v59n2.525
url https://rbc.inca.gov.br/index.php/revista/article/view/525
identifier_str_mv 10.32635/2176-9745.RBC.2013v59n2.525
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/525/320
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 59 No. 2 (2013): Apr./May/June; 201-210
Revista Brasileira de Cancerologia; Vol. 59 Núm. 2 (2013): abr./mayo/jun.; 201-210
Revista Brasileira de Cancerologia; v. 59 n. 2 (2013): abr./maio/jun. ; 201-210
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042244431118336